Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Recruiting2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06607692Phase 1Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT07072143RecruitingPrimary

An International Study on Pediatric Patients With Rare Tumors.

NCT06121271Phase 2Not Yet Recruiting

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Showing all 3 trials

Research Network

Activity Timeline